Status:
COMPLETED
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
Lead Sponsor:
Sanofi
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Hypertension
Eligibility:
All Genders
30-65 years
Phase:
PHASE4
Brief Summary
Primary objective: * To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria. Secondary objectives: * To determin...
Eligibility Criteria
Inclusion
- Hypertensive patients, treated or untreated, with type 2 diabetes and urinary albumin excretion rate 20-200ug/min.
- Blood pressure of \< 180/110mmHg at baseline
- Normal serum creatinine
Exclusion
- Type 1 diabetes
- Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in the 5 weeks before recruitment
- Pregnant or lactating women
- Severe hypertension
- Overt nephropathy
- Allergy to study drug
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT00334581
Start Date
May 1 2006
End Date
June 1 2008
Last Update
September 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Shanghai, China